Bezisterim for Long COVID Brain Fog and Fatigue

Phase 2 Long COVID trials face high failure rates; cognitive endpoints in this population are notoriously noisy with large placebo effects. Bezisterim (NE3107) previously failed its Phase 3 Alzheimer's trial in 2023, weakening prior. Cogstate composite z-score over 12 weeks is sensitive but variable. BioVie has disclosure/financial pressure. Small Phase 2 with subjective fatigue overlay lowers odds of clean statistical win.

Phase 2 in heterogeneous long-COVID brain fog/fatigue with an objective Cogstate composite at 12 weeks. Change-from-baseline design can be noisy and practice effects complicate interpretation; recruiting status near primary completion adds execution/disclosure risk. Endpoint is relevant but efficacy signal risk is high.

Phase 2 recruiting trial with objective Cogstate composite endpoint at 12 weeks; no sample size, power, or prior efficacy data in fields; heterogeneous long COVID population and early-stage status raise null-result risk.

Long COVID brain fog is highly heterogeneous, making objective endpoints like Cogstate noisy and prone to placebo effects. Sponsor BioVie recently suffered severe GCP violations in a Phase 3 Alzheimer's trial, raising major operational risks. Given the mixed prior clinical evidence for bezisterim and high variance in Long COVID trials, the probability of a statistically significant success is low.

Bezisterim previously failed a Phase 3 Alzheimer's trial, reducing confidence in neurocognitive efficacy. Long COVID brain fog is heterogeneous with high placebo response. Phase 2 success rates are low. Endpoint is objective but may lack sensitivity. Intrinsic probability ~18%.

Bezisterim has no prior efficacy data in Long COVID; anti-inflammatory mechanism is plausible but unproven for brain fog. Trial still 'Recruiting' with primary completion in 5 days is a major red flag—unlikely all patients completed 12-week treatment. BioVie's poor execution track record (Alzheimer's trial data integrity issues) adds operational risk. Composite cognitive endpoints are noisy. Low probability of statistically significant positive result.

Phase 2 Long COVID trials face high variability and placebo effects. Cogstate is sensitive but the indication is heterogeneous. BioVie's prior data is promising but not definitive for this specific population. High risk of failure due to noise in subjective/objective hybrid endpoints.

Phase 2 recruiting trial for a novel anti‑inflammatory (NE3107) in long‑COVID cognitive impairment. No prior efficacy data. Endpoint is a composite Cogstate score, which is sensitive but may be noisy in a heterogeneous patient group. Small sample size and high placebo response risk, plus recruitment challenges, make the intrinsic chance of a positive result modest (~35%).

Small Phase 2 Long COVID trial (NCT06847191) with subjective endpoint. Bezisterim failed prior Phase 3 in AD. Long COVID heterogeneity limits signal detection. Cogstate battery is sensitive but 12-week cognitive composite in post-viral syndrome has high placebo response and poor historical success. Sponsor BioVie has limited track record. Only 5 days to completion with no data disclosure yet raises execution risk. Low prior probability of success in this indication and mechanism.

Phase 2 trial for Long COVID brain fog is high-risk given the notoriously difficult-to-treat indication and recruiting status with primary completion in 5 days suggesting possible delays. Cogstate battery is an objective endpoint, but prior data for Bezisterim in cognitive indications is limited. Phase 2 cognitive trials historically have ~30-40% success rates. The trial may still be enrolling, making imminent results uncertain.